The APOE4 Vagus Nerve Stimulation Study: Results and How to Join Phoenix's Next Study
Adherence, self-report and wearable lessons from an observational study.
Key takeaways · TL;DR
Adherence, self-report and wearable lessons from an observational study.
Hi Phoenix friend,
31 APOE4 carriers logged 656 days of ear-based vagus nerve stimulation (taVNS) with ZenoWell.
First lesson: people kept using it. Twenty-three of 31 carriers logged at least 10 use days. Seventeen reached at least 20 days. A device cannot create useful evidence if it stays in a drawer.
Second lesson: the self-reported signals were positive (but small). In the 10-person paired subset, average energy was 0.33 points higher after reported use nights. Wellbeing was 0.28 points higher and sleep quality was 0.17 points higher.
Third lesson: wearables data is VERY promising. Sleep score was 2.1 points higher in a six-person subset. HRV was 3.9 ms higher in a nine-person subset. Total sleep time was about five minutes lower, and resting heart rate stayed flat.
Those nulls matter. So do the limits. This was observational, not randomized. All confidence intervals included no effect, the paired samples were small, and overlapping interventions may have influenced the results.
About the ZenoWell Luna: Want to try it? Phoenix readers can save 20% with code APOE4 at zenowell.ai/PHOENIX.
Phoenix connected daily check-ins, wearables, biomarkers and intervention timing to find those leads. Each cohort leaves the next one with a cleaner baseline, sharper outcomes and a stronger protocol.
That is how a carrier-led platform compounds into better studies: more carriers contribute, the evidence becomes more useful and the next study starts stronger.
Cheers,
Kevin
Phoenix does not provide medical advice, diagnosis or treatment. This observational analysis does not establish causation. Consult a qualified physician before changing any health protocol.
